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Enrico MaggiIt is my pleasure and honour to introduce the new
Clinical and Molecular Allergy (CMA), an open access,
peer-reviewed journal published by BioMed Central,
which in 2015 has re-launched as the official journal of
the Italian Society of Allergology, Asthma and Clinical
Immunology (SIAAIC). SIAAIC is the oldest scientific
society of the discipline in Italy which is strongly repre-
sented on the national territory with more than 650 active
members working in University structures, Hospital de-
partments and Territorial outpatients' clinics. SIAAIC is
the only Italian society represented at the European level
(EAACI).
The editorial team of the journal has been com-
pletely renewed, and can be accessed here(http://www.
clinicalmolecularallergy.com/about/edboard). The Editor-
in-Chief is the president-elect of SIAAIC and the new
Deputy and Section Editors are members of the National
Committee of the Society, all displaying an international
relevance in the field. The new members of the Editorial
Board, competent to cover the majority of fields of
basic, translational and clinical Allergology and Clinical
Immunology, are strongly motivated scientists, many of
them known worldwide. They are responsible for the
scientific quality and originality of publications in addition
to serving as journal advocates. The primary objective of
the editorial team is to reach and maintain a strong
Impact Factor within few years and the main aims of
the journal are:
I. To offer a prompt publication of results from original
research on the up-to-date topics of experimental and
clinical allergy and immunology for scientists of our
discipline.
II. To share opinions among the readers with top
scientists and clinical practicioners.Correspondence: enrico.maggi@unifi.it
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unless otherwise stated.III. To have a very easy instrument for students and
young specialists to update novelties in semestral
selected reviews focused on the section topics.
IV. To share knowledge on fields of common interest
with other physicians and researchers interested in
allergy and clinical immunology.
Six editorial sections have been chosen to cover the
majority of topics in basic translational and clinical allergy
and immunology. Sections include asthma, food, drug and
insect allergy, clinical and molecular allergy, allergy
immunotherapy, biologicals and clinical immunology.
Articles may range from pathogenetic studies on diseases
to clinical trials on novel therapies, giving insights into
underlying mechanisms of diseases, new methodologies
and other traslational and clinical topics which inform the
specialist and contribute to improve the diagnosis and
management of patients.
SIAAIC have chosen to affiliate with CMA for its open
access publishing model [1-4]. Open access journals have
the potential to reach a much larger set of readers than
any subscription-based journal, in print and online [5].
Studies have suggested a correlation between open access,
higher downloads and higher citations, leading to a higher
Impact Factor [6]. Furthermore articles are freely and
universally accessible online, so an author's work is available
to readers at no cost and not limited by their library’s
budget. This ensures that author’s work is disseminated to
the widest possible audience. Additional advantages include:
I. Authors hold copyright for their work and grant
anyone the right to reproduce and disseminate the
article.
II. The journal’s articles will be archived in PubMed
Central [7]. This complies with the policies of a
number of funding bodies as the Wellcome Trust,
NIH and Howard Hughes Medical Institute [8,9].
III. A country's economy will not influence its
researchers' ability to access articles becauses an Open Access article distributed under the terms of the Creative Commons
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SIAAIC wants to make this journal available to young
scientists (from the society, but not only limited to) who
need to quickly publish their results and receive feedback
from experienced colleagues to proceed with their studies.
The availability of semestral reviews on very hot topics
from high level scientists, one on clinical immunology
and the other in Allergology, as well as annual editorials
highlighting the most relevant improvement on their fields
from the Deputy and Section editors may contribute to in-
crease contacts with the CMA website from a large inter-
ested audience. This will further develop the journal and
its Impact Factor.
Allergology and Clinical Immunology is a quickly
evolving discipline where novelties must circulate in real
time. An open access journal as CMA is needed in this
field since is the most easy platform to communicate new
data and to share opinions or criticisms among scientists,
specialists and clinicians of close disciplines. The rapid
dissemination of the new knowledge guaranteed by the
journal will greatly enhance the value of research in the
field.
In the era of several exciting discoveries on basic
immunology and pathophysiological mechanisms of
immuno-mediated diseases, of new diagnostic laboratory
technologies for such disorders and novel therapeutical
drugs as biological/biosimilar agents, the journal plans to
publish periodic reviews on very hot topics from high level
scientists as well as one annual editorial highlighting the
most relevant improvement on the fields. The open access
platform of CMA to research on basic and clinical allergy
and immunology eliminates obstacles and challenges to
dissemination of such knowledge and provides a platform
for rapid discovery.
As a standard CMA will publish:
I. Research articles reporting original data from clinical
and basic research providing insights also into
physiopathological mechanisms, novel methodologies
and therapeutical protocols.
II. Reviews giving exhaustive and authoritative overviews
of any subjects within the journal’s scope, including
clinical molecular aetiopathogenetic aspects of allergy
and immuno-mediated disorders.
III. Case Reports providing molecular insights and
mechanisms governing common and rare diseases.
IV. Commentaries as short focused articles reporting
opinions on different issues within the journal
subjects.
V. Correspondences in the form of a re-analysis of a
previously published articles, or a reply to this re-
analysis from the authors of the original publication,or a short article that may not cover “standard
research” but is relevant for the specialists.
Of note, all articles will be published online immedi-
ately upon acceptance (after peer review) and soon after
listed in PubMed.
CMA operates a closed peer review process. Submissions
felt to be suitable for consideration will be sent for peer re-
view with appropriate independent experts. Handling
Editors will make a decision based on the reviewers’ re-
ports and authors are sent these reports along with the
editorial decision on their manuscript. Reviewers have
to evaluate originality and novelties of papers, taking
into account potential plagiarism, subject’s privacy and
ethical aspects. The journal operates a closed, single
blined peer review process whereby reviewers will be
treated anonymously. The CMA Editors agreed to adhere
the Code of conduct for Editors-in-Chief and the pub-
lisher’s policies. They check manuscripts on submission to
ensure they conform with these policies.
I hope that the new CMA may become a global forum
for the exchange of research and information on allergy,
asthma and clinical immunology, an exciting opportunity to
publish original results for young specialists and scientists.
Enrico Maggi, MD
Editor in Chief, Clinical and Molecular Allergy
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